RESEARCH ARTICLE

Quercetin Represses Apolipoprotein B Expression by Inhibiting the Transcriptional Activity of C/EBPβ

Makoto Shimizu*, Juan Li*, Jun Inoue, Ryuichiro Sato*

Department of Applied Biological Chemistry, The University of Tokyo 1-1-1 Yayoi, Bunkyo, Tokyo, Japan

☯ These authors contributed equally to this work.
* aroysato@mail.ecc.u-tokyo.ac.jp

Abstract

Quercetin is one of the most abundant polyphenolic flavonoids found in fruits and vegetables and has anti-oxidative and anti-obesity effects. Because the small intestine is a major absorptive organ of dietary nutrients, it is likely that highly concentrated food constituents, including polyphenols, are present in the small intestinal epithelial cells, suggesting that food factors may have a profound effect in this tissue. To identify novel targets of quercetin in the intestinal enterocytes, mRNA profiling using human intestinal epithelial Caco-2 cells was performed. We found that mRNA levels of some apolipoproteins, particularly apolipoprotein B (apoB), are downregulated in the presence of quercetin. On the exposure of Caco-2 cells to quercetin, both mRNA and protein levels of apoB were decreased. Promoter analysis of the human apoB revealed that quercetin response element is localized at the 5’-proximal promoter region, which contains a conserved CCAAT enhancer-binding protein (C/EBP)-response element. We found that quercetin reduces the promoter activity of apoB, driven by the enforced expression of C/EBPβ. Quercetin had no effect on either mRNA or protein levels of C/EBPβ. In contrast, we found that quercetin inhibits the transcriptional activity of C/EBPβ but not its recruitment to the apoB promoter. On the exposure of Caco-2 cells to quercetin 3-O-glucuronide, which is in a cell-impermeable form, no notable change in apoB mRNA was observed, suggesting an intracellular action of quercetin. In vitro interaction experiments using quercetin-conjugated beads revealed that quercetin binds to C/EBPβ. Our results describe a novel regulatory mechanism of transcription of apolipoprotein genes by quercetin in the intestinal enterocytes.

Introduction

Quercetin is one of the most abundant flavonoids present in a wide variety of fruits and vegetables, including onions, and has several beneficial properties against metabolic diseases through anti-oxidative and anti-inflammatory effects [1]. Several studies demonstrated that oxidative stress and other reactive oxygen species play important roles in the development of cancer,
neurodegenerative disease, and diabetes. Among polyphenolic flavonoids, quercetin and luteolin show the strongest anti-oxidative activity. Moreover, the anti-diabetic effects of quercetin against type 1 [2] and type 2 [3] diabetes have been reported. Although quercetin exerts beneficial effects on metabolic diseases, few molecular targets of quercetin have been identified. The small intestine is a major absorptive tissue of dietary nutrients. After their intestinal absorption, the flavonoids among them are likely to be conjugated and excreted efficiently in the urine, resulting in a lower accumulation of quercetin in the body [4–6]. Because concentrated food constituents may be present in the small intestinal epithelial cells, food factors may exert a more profound effect in this tissue compared with other organs.

In this study, we performed mRNA profiling to identify novel targets of quercetin in the intestinal enterocytes. We found that quercetin reduces the gene expression of apolipoproteins, including apolipoprotein B (apoB), in the human intestinal epithelial Caco-2 cells. Both mRNA and proteins of apoB were decreased by the quercetin treatment. Promoter analysis of the human apoB shows that a CCAAT enhancer-binding protein (C/EBP)-response element is important for the quercetin action. Furthermore, we found that quercetin binds C/EBPβ protein, thereby inhibiting its transcriptional activity. These results demonstrate a novel mechanism underlying the transcriptional regulation of apolipoprotein genes by quercetin in the small intestine.

Materials and Methods

Materials

Quercetin was obtained from Jena Bioscience. Quercetin 3-O-glucuronide and the protease inhibitor cocktail were obtained from Sigma.

Antibodies

Anti-apoB antibody (ab7616) was obtained from Abcam, anti-β-actin antibody (A5441) was obtained from Sigma, anti-C/EBPβ antibody (sc-150) was obtained from Santa Cruz Biotechnology, and anti-lamin antibody (2032) was obtained from cell signaling technology.

Cell culture

Caco-2 cells were maintained in medium A (Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, non-essential amino acids, 100 units/mL penicillin, and 100 μg/mL streptomycin) at 37°C in an atmosphere containing 5% CO₂. Except for transfection experiments and chromatin immunoprecipitation (ChIP) assays, cells that had been cultured for 14 days after confluency were considered differentiated. HepG2 cells were maintained in medium B (Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 μg/mL streptomycin) at 37°C in an atmosphere containing 5% CO₂. Caco-2 cells and HepG2 cells were purchased from ATCC.

Plasmids

Luciferase reporter plasmids for human apoB promoters were constructed using Kpnl/BglII PCR fragments coding for the indicated 5’-untranslated regions of human apoB into a pGL3-Basic vector (Promega). A luciferase reporter plasmid for C/EBP-response element (C/EBP-RE) was constructed using a double-stranded DNA coding four copies of C/EBP-RE of mouse C/EBPα promoter into a pGL3 promoter vector containing the promoter for simian virus 40 (SV40) (Promega). An expression plasmid for GAL4-hC/EBPβ (amino acid residues 1–345) was constructed by inserting a PCR fragment, which encodes human C/EBPβ into an
expression plasmid for the DNA-binding domain of the yeast transcription factor GAL4 (pCMX-GAL4).

An expression plasmid for pcDNA-hC/EBPβ was provided by Dr. Hidetoshi Hayashi. A reporter plasmid for yeast GAL4 (TK-MH100x4-Luc) and an expression plasmid for pCMX-GAL4 were provided by Drs. David J. Mangelsdorf and Steven A. Kliewer.

Co-transfection and luciferase assay

Caco-2 cells were placed in a 12-well plate at a density of 1.5 × 10^5 cells/well, cultured with medium A for 24 h, and then transfected with 500 ng of one of the reporter plasmids and 500 ng of pCMV-β-Gal, an expression plasmid for β-galactosidase, using the calcium phosphate method. For co-transfection experiments, 250 ng of one of the reporter plasmids, 250 ng of pCMV-β-Gal, and 500 ng of each of the expression plasmids were added. Twenty four hours after transfection, medium was replaced with medium A and vehicle or the indicated compounds were added. After incubation for an additional 24 h, the luciferase and β-galactosidase activities were determined, as described previously [7]. Normalized luciferase values were determined by dividing the luciferase activity by the β-galactosidase activity.

Western blot analysis

Caco-2 cells were differentiated by continuous culture for 14 days after they reached confluency. After treatment, cells were harvested, and western blot analysis was performed, as described previously [8].

Real time PCR

Total cell RNA was extracted using ISOGEN (NIPPON GENE) according to the manufacturer’s instructions. The high capacity cDNA reverse transcription kit (Applied Biosystems) was used to synthesize and amplify cDNA from total RNA. Quantitative real-time PCR (SYBR green and TaqMan) was performed using an Applied Biosystems 7000 sequence detection system. Relative mRNA levels were determined by normalizing to the 36B4 transcript. The sequences of the primer sets used in this study were as follows: 36B4 [9], 5′−TGGATACAGCCTCGTGTTTGGATCGAGCTT−3′ and 5′−AAAGCAGTATCCACCACACAGA−3′; apoB [10], 5′−GCCAAGCAGAAAATA−3′ and 5′−TGACTTGGTGTGATTGCAGCTT−3′; apoCII, 5′−TGGGAGTAGAGACA−3′ and 5′−GGCGTGAGATGGCATG−3′; apoCIII, 5′−GCTCATCTTATCCA−3′ and 5′−CGGCCCTCTGAGATTCG−3′; apoE, 5′−TGCGTTGCTGGGCTATT−3′ and 5′−CTGGCTCCACCAGCTTG−3′; and MTP, 5′−TGTGCTTTTCTCTGTTACATT−3′ and 5′−GCTTGTACAGCGCGTATTATTT−3′. The TaqMan ID number for apoA-I is Hs00163641_m1.

ChIP assay

Caco-2 cells were grown in 10-cm dishes with medium A to confluency, followed by treatment with vehicle or 100 μM quercetin for 10 h. The cells were then processed for ChIP assay using a reagent kit (Millipore), as recommended by the manufacturer. Immunoprecipitation was performed with normal rabbit IgG (Santa Cruz Technology) or an anti-C/EBPβ antibody (Santa Cruz Technology). Real time PCR used the following primers: human apoB C/EBP-RE, 5′−CTTCAAGGCTCAAGAGGAGAAC−3′ and 5′−AGGTCAGGCTGGCAATG−3′ and human apoB distal region, 5′−GGGCACAGTTCCATCTACAA−3′ and 5′−CCTATCTCGTTTCTGCTAT−3′.
Binding assay using quercetin-conjugated beads

Quercetin-conjugated agarose beads and their control beads were provided from RIKEN NPDepo [11]. After Caco-2 cells were treated with vehicle or 100 μM quercetin for 12 h, cells were collected with the binding buffer [10 mM Tris-HCl (pH 7.6), 50 mM KCl, 5 mM MgCl2, 1 mM EDTA, and a protease inhibitor cocktail]. Cell lysates (1 mg of protein) were precleared by control beads (10 μl) and then incubated with quercetin beads or control beads (15 μl) for 12 h at 4°C. The reacted beads were washed with the binding buffer, and co-precipitated proteins were detected by western blot analysis.

Statistical analysis

All results are presented as mean ± standard deviation (±SD) and evaluated using the Student’s t-test. Significance was assumed at p < 0.05 and p < 0.01.

Results

Expression of apolipoproteins is decreased by quercetin

Human intestinal epithelial Caco-2 cells were used to identify novel targets of quercetin in the intestinal enterocytes. Total RNA was prepared from differentiated Caco-2 cells cultured with 100 μM quercetin for 24 h. Then mRNA levels of several genes related to lipid metabolism were analyzed by quantitative real time PCR. This mRNA profiling revealed that the gene expression of some apolipoproteins, including apolipoprotein A-I (apoA-I) and apoB, was significantly decreased by quercetin (Fig 1A). In addition, we observed downregulation of gene expression of microsomal triglyceride transfer protein (MTP), which has a crucial role in chylomicron and very low density lipoprotein (VLDL) assembly. Because apoB expression was markedly suppressed by quercetin, we decided to focus on further analyzing the regulation of apoB gene expression. Exposure of quercetin for 12 h was enough to suppress apoB expression (S1 Fig). Caco-2 cells synthesize both apoB48 and apoB100, although they are produced in vivo in the intestine and liver, respectively [12]. Western blot analyses revealed that both intracellular apoB48 and apoB100 proteins were decreased by the quercetin treatment for 12 h (Fig 1B). ApoB expression was decreased at 50 and 100 μM quercetin (Fig 1C). These results indicate that quercetin reduces apoB expression both in mRNA and protein levels.

A C/EBP-response element in the ApoB promoter mediates quercetin action

To investigate the mechanism underlying the quercetin-mediated suppression of apoB expression, reporter gene assays were performed. We generated a reporter gene construct located in the 1.8k upstream region of the human apoB. When Caco-2 cells were treated with quercetin, the promoter activity of the 1.8k upstream region was significantly decreased (Fig 2A). To determine the precise region of the quercetin-response element, we next generated a series of deletion constructs of the upstream region of apoB. Reporter gene assays showed that the promoter activity suppressed by quercetin was not affected by deleting the region between −1298 bp and −73 bp, even though the repression of the promoter activity by quercetin slightly diminished when the region between −574 bp and −73 bp was deleted (Fig 2B). In contrast, the inhibitory effect of quercetin on the promoter activity was completely abolished when the region between −73 bp and −29 bp was deleted, indicating that this region includes the quercetin-response element (Fig 2B). The DNA sequence analysis using CLUSTALW alignment software revealed that the region between −71 bp and −54 bp was highly conserved among species. This DNA sequence was previously reported as the CCAAT enhancer-binding protein
Fig 1. Quercetin repressed the expression of genes related to lipoprotein metabolism in Caco-2 cells. (A) Differentiated Caco-2 cells were treated with vehicle or 100 μM quercetin for 24 h, after which total RNA was isolated. mRNA levels, which were determined by quantitative real-time PCR, are presented as relative expression after normalization to 36B4 mRNA. Relative mRNA levels in vehicle-treated cells were set to 1. Data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01. (B) Differentiated Caco-2 cells were treated with vehicle (Veh) or 100 μM quercetin (Q) for 12 h. Proteins were extracted and immunoblots (IB) were performed. (C) Differentiated Caco-2 cells were exposed to vehicle or the indicated doses of quercetin for 24 h, after which total RNA was isolated. Data are presented as mean ± SD (n = 3). **p < 0.01.

doi:10.1371/journal.pone.0121784.g001
Fig 2. Identification of the quercetin-response element of the human apoB promoter. (A, B, D) Caco-2 cells were transfected with the reporter gene, which contains the indicated upstream region of human apoB and an expression plasmid for β-galactosidase. After transfection, cells were exposed to vehicle or 100 μM quercetin for 24 h. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of quercetin. Data are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, N.S., not significant. (C) DNA sequences of the human apoB (NT_022184), mouse apoB (NC_000078), and rat apoB.
(C/EBP)-response element [13–15] (Fig 2C). The suppression of the promoter activity caused by quercetin was abolished when the C/EBP-response element sequence was mutated (Fig 2D). These results suggest that quercetin repressed transcription of apoB through C/EBP.

Quercetin inhibits the C/EBPβ-mediated activation of the apoB promoter

Because C/EBPβ regulates the intestinal expression of apoB among C/EBP family proteins [16], we investigated the effect of C/EBPβ on the quercetin-response element. Reporter gene assays using C/EBPβ expression plasmid were performed. When C/EBPβ was expressed in Caco-2 cells, the promoter region between −73 bp and +42 bp was strongly activated (−73 bp, Fig 3B). In contrast, deletion of the quercetin-response element (−29 bp, Fig 3B) or mutating the C/EBP-response element (Fig 3C) strongly reduced the promoter activation by C/EBPβ. Furthermore, we examined whether quercetin represses the C/EBPβ-mediated activation of the apoB promoter. Reporter gene assay showed that the stimulation of the apoB promoter by C/EBPβ was significantly reduced in the presence of quercetin (WT, Fig 3D). However, a mutation in the C/EBP-response element abolished the suppression of C/EBPβ-driven promoter activation by quercetin (mut, Fig 3D). To confirm a common inhibitory role of quercetin on C/EBPβ target genes, reporter gene assay using the artificial promoter containing four copies of C/EBP-response elements derived from the mouse C/EBPα promoter (C/EBP-REx4-Luc, Fig 3A) was performed. Similar to the apoB promoter, quercetin repressed the C/EBPβ-mediated activation of C/EBP-REx4-Luc (Fig 4D). These results indicate that quercetin inhibits the promoter activation mediated by C/EBPβ.

C/EBPβ expression is not affected by quercetin

Because quercetin inhibits the induction of C/EBPβ protein in response to the proteasome inhibitors [17], we hypothesized that quercetin regulates apoB transcription through decreased C/EBPβ proteins. To investigate the protein levels of C/EBPβ, nuclear extracts were prepared from Caco-2 cells treated with quercetin for 12 h. Western blot analyses showed no detectable changes of nuclear C/EBPβ proteins by quercetin (Fig 4A). Quantitative real time PCR analyses similarly revealed that quercetin has no effect on the mRNA level of C/EBPβ (Fig 4B). These results indicate that quercetin does not affect C/EBPβ expression in Caco-2 cells.

Transcriptional activity, but not DNA-binding activity, of C/EBPβ is inhibited by quercetin

We next performed ChIP assays to examine the DNA-binding activity of C/EBPβ. Caco-2 cells were exposed to 100 μM quercetin for 10 h, and then chromatin was prepared. To isolate the C/EBPβ-bound genomic DNA, a chromatin immunoprecipitation by C/EBPβ antibody was performed. Quantitative real time PCR was used to detect the recruitment of C/EBPβ to the promoter using primer sets covering the region containing the C/EBP-response element (C/EBP-RE) or the upstream control region, which lacked C/EBP-RE (−3 kb, distal) of apoB. We observed that C/EBPβ was selectively recruited to C/EBP-RE but not the distal region (Fig 5A). This DNA-binding of C/EBPβ was not decreased in the presence of quercetin, suggesting that quercetin reduces apoB expression, independent of the DNA-binding activity of C/EBPβ.
**Fig 3. Quercetin inhibits the C/EBPβ-mediated activation of the human apoB promoter.** (A) A map of the reporter plasmids was used. Gray circles, C/EBP-response element; closed box, SV40 promoter. (B,C) Caco-2 cells were transfected with the indicated reporters and expression plasmids for β-galactosidase and C/EBPβ. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of C/EBPβ. Data are presented as mean ± SD (n = 3). **p < 0.01. (D,E) Caco-2 cells were transfected with the indicated reporters and expression plasmids for β-galactosidase and C/EBPβ. After transfection, cells were treated with vehicle or 100 μM quercetin for 24 h. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of C/EBPβ. Data are presented as mean ± SD (n = 3). **p < 0.01, N.S., not significant.
Fig 4. C/EBPβ expression was not altered by quercetin. (A) Immunoblot (IB) analysis used nuclear extracts from differentiated Caco-2 cells treated with vehicle (Veh) or 100 μM quercetin (Q) for 12 h. (B) Differentiated Caco-2 cells were exposed to vehicle (Veh) or 100 μM quercetin (Q) for 12 h, after which total RNA was isolated. mRNA levels, which were determined by quantitative real-time PCR, are presented as relative expression after normalization to 36B4 mRNA. Relative mRNA levels in vehicle-treated cells were set to 1. Data are presented as mean ± SD (n = 3). N.S., Not significant.

doi:10.1371/journal.pone.0121784.g004
We next examined the transcriptional activity of C/EBPβ using a fusion construct containing human C/EBPβ and the DNA-binding domain of yeast transcription factor GAL4 (GAL4-hC/EBPβ). The transcriptional activity of this fusion protein was analyzed by the reporter, which contains a GAL4 DNA-binding target sequence (TK-MH100x4-Luc). As shown in Fig 5B, quercetin significantly reduced the activity of GAL4-C/EBPβ in HEK293 cells. These
results indicated that quercetin directly inhibits the transcriptional activity but not the DNA-binding activity of C/EBPβ.

**Quercetin binds to C/EBPβ**

We next examined whether quercetin affected the C/EBPβ transcriptional activity intracellularly. Quercetin 3-O-glucuronide (Fig 6A) is not absorbed efficiently compared with quercetin aglycone [18]. Caco-2 cells were treated with these flavonoids for 24 h, and then mRNA was prepared for mRNA analysis. We observed that quercetin aglycone, but not quercetin 3-O-glucuronide, reduced apoB mRNA (Fig 6B), indicating the intracellular action of quercetin. Because significant amount of quercetin could be found in the nucleus [19], we hypothesized that quercetin directly works on nuclear C/EBPβ. To confirm the binding of quercetin to C/EBPβ, experiments using quercetin-immobilized agarose beads (quercetin beads) [11] were performed. Caco-2 cells were cultured in the presence of 100 μM quercetin for 12 h. Lysates prepared from Caco-2 cells were incubated with quercetin beads or equivalent control beads, and precipitated proteins with beads were detected by C/EBPβ antibody. Western blot analysis revealed that endogenous C/EBPβ proteins were coprecipitated with quercetin beads, whereas no associations with control beads were detected (Fig 6C, Lane 3 and 5). Moreover, the quercetin treatment reduced the C/EBPβ binding to quercetin beads, suggesting that C/EBPβ prepared from the cells incubated with quercetin was no longer able to associate with quercetin beads (Fig 6C, Lane 5 and 6). These results showed that quercetin binds to C/EBPβ after uptake by cells and represses the transcriptional activity of C/EBPβ.

**Discussion**

ApoB is a major apolipoprotein synthesized in the liver and small intestine and has an important role in the assembly and secretion of hepatic VLDL and intestinal chylomicrons. Overproduction of VLDL observed in insulin resistant states may lead to hypertriglyceridemia and atherosclerosis. In addition, plasma levels of chylomicrons are elevated in type 2 diabetes [20]. Along with apoB, MTP is also essential for the assembly of chylomicrons. Studies using the intestine specific MTP knockout mice [21] and intestine selective MTP inhibitors [22] demonstrated that a loss of MTP function in the small intestine improves the plasma lipid parameters. These observations suggest that an inhibition of intestinal chylomicron production may contribute to medical therapy for obesity and diabetes. Our present study revealed that quercetin reduces expression of several genes related to lipoprotein metabolism, including apoB and MTP (Fig 1A), indicating an effective inhibition of chylomicron formation by quercetin. Previous studies reported C/EBP-response elements in the promoter region of some apolipoprotein genes [23], suggesting that quercetin regulates the expression of these genes by inhibiting C/EBPβ. In addition, quercetin represses the secretion of apoB in the enterocytes [24] and hepatocytes [25]. Furthermore, anti-obesity and anti-diabetic effects of quercetin have been reported [2,26]. These studies support the physiological relevance of our present results. Future in vivo studies may be required to verify the reduction of intestinal apolipoprotein expression and chylomicron production by quercetin.

ApoB expression is regulated by several steps, such as transcription, mRNA editing, and proteosomal degradation. Hepatocyte nuclear factor 3 (HNF3), HNF4, and C/EBP are the key transcriptional regulators of apoB [13]. Hepatic C/EBPa binds to the C/EBP response element of the apoB promoter [27], whereas it is unknown which C/EBP subtype binds to this sequence in the small intestine. In addition to the proximal promoter, intestinal apoB expression requires the intestinal enhancer in the upstream region. It has been reported that HNF4, HNF3β, and C/EBPβ bind to this enhancer region [28]. These prompted us to investigate C/EBPβ...
Fig 6. Intracellular quercetin binds to C/EBPβ. (A) Chemical structures of quercetin and quercetin 3-O-glucuronide. (B) Differentiated Caco-2 cells were treated with vehicle (Veh) or 100 μM quercetin (Q) or 100 μM quercetin 3-O-glucuronide (Q3G) for 24 h, after which total RNA was isolated. mRNA levels, which were determined by quantitative real-time PCR, are presented as relative expression after normalization to 36B4 mRNA. Relative mRNA levels in vehicle-treated cells were set to 1. Data are presented as mean ± SD (n = 3). *p < 0.05. (C) Caco-2 cells were exposed to vehicle (Veh) or 100 μM quercetin (Q) for 12 h, and cell lysates were prepared. Pre-cleared lysates with control beads were incubated with control (Ctrl) beads or quercetin (Q)-conjugated beads. The reacted beads were washed, and the coprecipitated proteins were detected by immunoblot (IB) analysis.

doi:10.1371/journal.pone.0121784.g006
association to the C/EBP-response element in the proximal apoB promoter. Our present study revealed that endogenous C/EBPβ binds to the promoter region in Caco-2 cells (Fig 5A). However, these results do not rule out the possibility of involvement of other C/EBP family members. Previous studies reported that some C/EBP subtypes, including C/EBPα, are also expressed in the small intestine [29]. Moreover, we observed that quercetin represses the C/EBPα-mediated activation of the apoB promoter in Caco-2 cells by the reporter gene assay (S2 Fig). Further studies including the analysis of transcriptional regulation of apoB by other C/EBP subtypes are also needed.

Our results clearly show that the C/EBP-response element between −71 bp and −54 bp is crucial for quercetin-mediated repression of the apoB promoter (Figs 2D and 3D). Quercetin potently inhibited the promoter activity when the region between −574 bp and +42 bp was present. However, deleting the region between −574 bp and −73 bp resulted in the loss of inhibition although quercetin significantly, though not strongly, repressed the promoter activity (Fig 2B). In addition, quercetin reduced apoB-luc promoter activity of (−574 bp), even when the C/EBP-response element was mutated (S3 Fig). These results indicate that the unknown transcription factors other than C/EBP, which appear to bind the region between −574 bp and −73 bp, are also involved in quercetin-mediated repression of apoB gene expression. However, when C/EBPβ was exogenously expressed, quercetin-mediated repression of both the longer and shorter promoter activities was completely abolished by C/EBP-RE mutation (−73 bp mut and −574 bp mut in Fig 3D and S4 Fig, respectively). Therefore, it is clear that the C/EBP-response element located between −71 bp and −54 bp is responsible for a part of the quercetin-dependent downregulation of apoB gene expression. We observed a weak activation of the mutated promoters by C/EBPβ (Fig 3C and S4 Fig), which may have been caused by another C/EBP-response element located between −53 bp and −33 bp [13].

In addition to the small intestine, C/EBPβ is expressed in other tissues, including the liver [29]. We observed that quercetin suppressed apoB expression in the human hepatoma HepG2 cells (S5 Fig). Moreover, quercetin has been reported to inhibit apoB secretion from HepG2 cells [25]. These observations indicate that quercetin may act on apoB expression in the small intestine and liver.

Quercetin inhibits the induction of C/EBP protein [17] and the DNA-binding activity of C/EBPβ [30]. We did not observe these effects in the present study (Figs 4A and 5A), but an inhibition of the transcriptional activity of C/EBPβ by quercetin was demonstrated. It is possible that some distinct experimental conditions may cause the difference [17,30].

Along with C/EBP, HNF4 is also an important regulator of apolipoprotein expression. AMP-activated protein kinase (AMPK) promotes the degradation of HNF4 protein through phosphorylation [31,32]. HNF4 is highly expressed in the liver and small intestine [33], and quercetin is an activator of AMPK [34,35]. From these observations, we hypothesized that quercetin reduces apoB expression through the degradation of HNF4 protein. However, the reporter gene assay showed that quercetin does not inhibit the HNF4-mediated activation of the apoB promoter (S6 Fig), suggesting a selective action of quercetin on C/EBPβ in the small intestine.

In conclusion, RNA profiling studies using Caco-2 cells found that quercetin represses the gene expression of apolipoproteins, including apoB. Promoter analysis of the human apoB revealed the C/EBP-mediated action of quercetin. Furthermore, studies using GAL4-C/EBPβ and quercetin beads showed that quercetin binds to C/EBPβ and represses its transcriptional activity possibly by inhibiting the recruitment of coactivators (Fig 7). Overall, these results demonstrate a novel function of quercetin as a repressor of the apolipoprotein gene expression through its binding to C/EBPβ protein.
Supporting Information

S1 Fig. Quercetin exposure for 12 h reduces the expression of apoB gene.

Differentiated Caco-2 cells were treated with vehicle or 100 μM quercetin for 12 h, after which total RNA was isolated. mRNA levels, which were determined by quantitative real-time PCR, are presented as relative expression after normalization to 36B4 mRNA. Relative mRNA levels in vehicle-treated cells were set to 1. Data are presented as mean ± SD (n = 3). **p < 0.01.

(TIF)

S2 Fig. Quercetin inhibits the C/EBPα-mediated activation of the human apoB promoter.

Caco-2 cells were transfected with the indicated reporter [apoB-luc (−73b)] and expression plasmids for β-galactosidase and C/EBPα. After transfection, cells were treated with vehicle or 100 μM quercetin for 24 h. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of C/EBPα. Data are presented as mean ± SD (n = 3).

*A p < 0.05.

(TIF)

S3 Fig. Quercetin represses the promoter activity of a mutated reporter containing the −574 bp region of the apoB gene.

Caco-2 cells were transfected with the wild-type (WT) or the C/EBP-response element mutated (mut) reporter gene, which contains the indicated upstream region of human apoB and a β-galactosidase expression plasmid. After transfection, cells were exposed to vehicle or 100 μM quercetin for 24 h. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of quercetin. Data are presented as mean ± SD (n = 3).

*A p < 0.05, **p < 0.01.

(TIF)

S4 Fig. C/EBP-response element mediates repression of the apoB promoter through C/EBPβ by quercetin.

Caco-2 cells were transfected with the indicated reporters and expression plasmids for β-galactosidase and C/EBPβ. After transfection, cells were treated with vehicle or 100 μM quercetin for 24 h. Luciferase activities were normalized to β-galactosidase activities.
activities; a value of 1 was set in the absence of C/EBPβ. Data are presented as mean ± SD (n = 3). **p < 0.01, N.S., not significant.

S5 Fig. Quercetin reduces apoB expression on hepatocytes. HepG2 cells were treated with vehicle or 100 μM quercetin for 24 h, and the total RNA was isolated. mRNA levels were determined by quantitative real-time PCR, and are presented as relative expression after normalization to 36B4 mRNA. Relative mRNA levels in vehicle-treated cells were set to 1. Data are presented as mean ± SD (n = 3). **p < 0.01.

S6 Fig. Quercetin does not inhibit the HNF4α-mediated activation of the human apoB promoter. HEK293 cells were transfected with the indicated reporter [apoB-luc (−73b)] and expression plasmids for β-galactosidase, HNF4α, and C/EBPβ. After transfection, cells were treated with vehicle or 30 μM quercetin for 12 h. Luciferase activities were normalized to β-galactosidase activities; a value of 1 was set in the absence of HNF4α and C/EBPβ. Data are presented as mean ± SD (n = 3). **p < 0.01. N.S., Not significant.

Acknowledgments
We thank Ms. Kaori Honda, Drs. Yasumitsu Kondoh, Tamio Saito and Hiroyuki Osada (RIKEN NPDepo) for providing quercetin-conjugated agarose beads. We also thank Drs. David J. Mangelsdorf and Steven A. Kliewer (University of Texas Southwestern Medical Center) and Dr. Hidetoshi Hayashi (Nagoya City University) for providing plasmids.

Author Contributions
Conceived and designed the experiments: MS RS. Performed the experiments: MS JL. Analyzed the data: MS JL JI RS. Wrote the paper: MS RS.

References
1. Bischoff SC. Quercetin: potentials in the prevention and therapy of disease. Curr Opin Clin Nutr Metab Care. 2008; 11: 733–740. doi: 10.1097/MCO.0b013e328329e911 PMID: 18827577
2. Kobori M, Masumoto S, Akimoto Y, Takahashi Y. Dietary quercetin alleviates diabetic symptoms and reduces streptozotocin-induced disturbance of hepatic gene expression in mice. Mol Nutr Food Res. 2009; 53: 859–868. doi: 10.1002/mnfr.200800310 PMID: 19496084
3. Alam MM, Meerza D, Naseem I. Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci. 2014; 109: 8–14. doi: 10.1016/j.lfs.2014.06.005 PMID: 24946265
4. de Vries JH, Hollman PC, Meyboom S, Buysman MN, Zock PL, van Staveren WA, et al. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am J Clin Nutr. 1998; 68: 60–65. PMID: 9665097
5. Moon JH, Nakata R, Oshima S, Inakuma T, Terao J. Accumulation of quercetin conjugates in blood plasma after the short-term ingestion of onion by women. Am J Physiol Regul Integr Comp Physiol. 2000; 279: R461–467. PMID: 10938233
6. Mullen W, Edwards CA, Crozier A. Absorption, excretion and metabolite profiling of methyl-, glucuro- nyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr. 2006; 96: 107–116. PMID: 16869998
7. Sato R, Miyamoto W, Inoue J, Terada T, Imanaka T, Maeda M, et al. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999; 274: 24714–24720. PMID: 10451379
8. Inoue J, Ito Y, Shimada S, Satoh SI, Sasaki T, Hashidume T, et al. Glutamine stimulates the gene expression and processing of sterol regulatory element binding proteins, thereby increasing the
expression of their target genes. FEBS J. 2011; 278: 2739–2750. doi:10.1111/j.1742-4658.2011.08204.x PMID: 21696544

9. Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA, et al. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. J Biol Chem. 2003; 278: 52479–52490. PMID: 14563840

10. Takahashi M, Kanayama T, Yashiro T, Kondo H, Murase T, Hase T, et al. Effects of coumestrol on lipid and glucose metabolism as a farnesoid X receptor ligand. Biochem Biophys Res Commun. 2008; 372: 395–399. doi: 10.1016/j.bbrc.2008.04.136 PMID: 18457666

11. Kawatani M, Okumura H, Honda K, Kanoh N, Muroi M, Dohmae N, et al. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proc Natl Acad Sci U S A. 2008; 105: 11691–11696. doi: 10.1073/pnas.0712239105 PMID: 18695250

12. Luchoomun J, Zhou Z, Bakillah A, Jamil H, Hussain MM. Assembly and secretion of VLDL in nondifferentiated Caco-2 cells stably transfected with human recombinant ApoB48 cDNA. Arterioscler Thromb Vasc Biol. 1997; 17: 2955–2963. PMID: 9409282

13. Kardassis D, Zannis VI, Cladaras C. Organization of the regulatory elements and nuclear activities participating in the transcription of the human apolipoprotein B gene. J Biol Chem. 1992; 267: 2622–2632. PMID: 1733959

14. Metzger S, Leff T, Breslow JL. Nuclear factors AF-1 and C/EBP bind to the human ApoB gene promoter and modulate its transcriptional activity in hepatic cells. J Biol Chem. 1990; 265: 9978–9983. PMID: 2161847

15. Carlsson P, Eriksson P, Bjursell G. Two nuclear proteins bind to the major positive element of the apolipoprotein B gene promoter. Gene. 1990; 94: 295–301. PMID: 2258060

16. Antes TJ, Goodart SA, Huynh C, Sullivan M, Young SG, Levy-Wilson B, et al. Identification and characterization of a 315-base pair enhancer, located more than 55 kilobases 5' of the apolipoprotein B gene, that confers expression in the intestine. J Biol Chem. 2000; 275: 26637–26648. PMID: 10859308

17. Hungness ES, Robb BW, Luo GJ, Pritts TA, Hershko DD, Hasselgren PO, et al. Proteasome inhibitors activate the transcription factors C/EBP-beta and delta in human intestinal epithelial cells. Biochem Biophys Res Commun. 2002; 290: 469–474. PMID: 11779194

18. Murota K, Shimizu S, Chujo H, Moon JH, Terao J. Efficiency of absorption and metabolic conversion of quercetin and its glucosides in human intestinal cell line Caco-2. Arch Biochem Biophys. 2000; 384: 391–397. PMID: 11368329

19. Kanazawa K, Uehara M, Yanagitani H, Hashimoto T. Bioavailable flavonoids to suppress the formation of 8-OHdG in HepG2 cells. Arch Biochem Biophys. 2000; 455: 197–203. PMID: 17052680

20. Duez H, Pavlic M, Lewis GF. Mechanism of intestinal lipoprotein overproduction in insulin resistant humans. Atheroscler Suppl. 2008; 9: 33–38. doi: 10.1016/j.atherosclerosissup.2008.05.013 PMID: 18676184

21. Iqbal J, Parks JS, Hussain MM. Lipid absorption defects in intestine-specific microsomal triglyceride transfer protein and ATP-binding cassette transporter A1-deficient mice. J Biol Chem. 2013; 288: 30432–30444. doi: 10.1074/jbc.M113.501247 PMID: 24019513

22. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 2005; 5: 30. PMID: 16188040

23. Zannis VI, Kan HY, Krits A, Zanni E, Kardassiss D. Transcriptional regulation of the human apolipoprotein B gene. Front Biosci. 2001; 6: D456–504. PMID: 11229886

24. Casaschi A, Wang Q, Dang K, Richards A, Theriault A. Intestinal apolipoprotein B secretion is inhibited by the flavonoid quercetin: potential role of microsomal triglyceride transfer protein and diacylglycerol acyltransferase. Lipids. 2002; 37: 647–652. PMID: 12216835

25. Pal S, Ho N, Santos C, Dubois P, Mamo J, Croft K, et al. Red wine polyphenolics increase LDL receptor expression and activity and suppress the secretion of ApoB100 from human HepG2 cells. J Nutr. 2003; 133: 700–706. PMID: 12612140

26. Kobori M, Masumoto S, Akimoto Y, Oike H. Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice. Mol Nutr Food Res. 2011; 55: 530–540. doi: 10.1002/mnfr.201000392 PMID: 21462320

27. Metzger S, Halaas JL, Breslow JL, Sladek FM. Orphan receptor HNF-4 and bZIP protein C/EBP alpha bind to overlapping regions of the apolipoprotein B gene promoter and synergistically activate transcription. J Biol Chem. 1993; 268: 16831–16838. PMID: 8344962
Zannis VI, Kan HY, Kritis A, Zanni EE, Kardassis D. Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo. Curr Opin Lipidol. 2001; 12: 181–207. PMID: 11264990

Lekstrom-Himes J, Xanthopoulos KG. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J Biol Chem. 1998; 273: 28545–28548. PMID: 9786841

Xiao X, Shi D, Liu L, Wang J, Xie X, Kang T, et al. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. PLoS One. 2011; 6: e22934. doi:10.1371/journal.pone.0022934 PMID: 21857970

Hong YH, Varanasi US, Yang W, Leff T. AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability. J Biol Chem. 2003; 278: 27495–27501. PMID: 12740371

Leclerc I, Lenzner C, Gourdon L, Vaulont S, Kahn A, Viollet B, et al. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes. 2001; 50: 1515–1521. PMID: 11423471

Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell. 2006; 126: 789–799. PMID: 16923397

Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, Saha AK, et al. Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. Biochem Biophys Res Commun. 2009; 378: 836–841. doi:10.1016/j.bbrc.2008.11.130 PMID: 19071085

Ahn J, Lee H, Kim S, Park J, Ha T. The anti-obesity effect of quercetin is mediated by the AMPK and MAPK signaling pathways. Biochem Biophys Res Commun. 2008; 373: 545–549. doi: 10.1016/j.bbrc.2008.06.077 PMID: 18586010